ReviewMolecular biology reports2025
Mechanistic insight into nanomedicine for polycystic ovary syndrome.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Gene Function to Precision Intervention: CRISPR/Cas9 and Stem Cell-Based Strategies as Emerging Disease-Modifying Approaches in PMOS.Stem cell reviews and reports · 2026Review
- Exploring the role of medicinal plants and nanotechnology in the management of polycystic ovarian syndrome (PCOS): a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Macrophage Membrane-Cloaked, ROS-Triggered Quercetin Nanocarriers Target Ovarian Lesions to Treat Polycystic Ovary Syndrome.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disorder. It is the most prevalent disease in reproductive-aged females worldwide. PCOS is characterized by hormonal imbalance, chronic anovulation, and metabolic dysfunction. The complex etiology of PCOS, which involves genetic, environmental, and lifestyle factors, contributes to the variability in its clinical presentation and complicates treatment strategies. Current therapeutic and disease management options, including hormonal therapy, and insulin sensitizers are limited by the side effects associated with non-targeted approach. In recent years, nanomedicine has emerged as a promising approach to overcome these challenges. It offers enhanced bioavailability, targeted drug delivery, and reduced systemic toxicity. Nanoparticles (NPs) possess unique physicochemical properties including high drug loading capacity and a large surface area. They can bind both hydrophilic and hydrophobic substances. These characteristics make NPs a promising platform for targeted and controlled drug delivery. Challenges such as off-target effects and limited efficacy in traditional therapy are mitigated when therapeutic agents are combined with nanoparticles, increasing precision and therapeutic outcomes. This review provides a comprehensive summary of the unique properties of nanoparticles that play crucial roles in their interactions with reproductive systems. Further we focus on the mechanistic insights into how nanoparticles modulate key PCOS-related pathways, including insulin signaling, steroidogenesis, inflammation and oxidative stress. This review highlights the role of some specific nanocarriers (e.g.; curcumin loaded NPs, selenium NPs, and exosomes) in restoring metabolic and reproductive functions in PCOS. In addition, we discuss NPs synthesis, delivery mechanisms, and their interactions at the molecular and cellular levels to PCOS pathology, with their putative role in pathway linked modulation of insulin resistance, hyperandrogenism, inflammation, and disrupted folliculogenesis. Understanding these mechanisms is essential for designing effective, nanomedicine for PCOS and possibly for other PCOS related chronic diseases.
Indexed as
Identifiers
40544202What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.